Skip to main content
SpringerLink
Log in
Book cover

Tumors of the Chest pp 439–450Cite as

Non-Small-Cell Lung Cancer: Clinical Studies in Europe

  • Chapter

  • 810 Accesses

37.4 Conclusion

Investigators from Europe have always played an active role in the clinical development of new treatment strategies and innovative drugs, and they have made valuable contributions to establishing new treatment standards for patients with NSCLC. The most recent results of the IALT study are particularly noteworthy because they mark a first step toward postoperative, adjuvant chemotherapy of NSCLC. Clinical research in Europe prepared well for its tasks over the three decades since 1975, giving rise to a large number of national and supranational high-quality, high-performance cooperative groups. As a result of their close connections with national tumor centers, and especially their clinical and diagnostic units, these groups clearly meet the increasing requirements of current and future clinical research. A good example is the growing cooperation between the EORTC, the primary European organization for clinical cancer research, and highly renowned North American study groups as well as national tumor centers. And there is no doubt that the political changes of the last 15 years have expanded Europe’s capability to perform high-quality clinical trials even further, irrespective of the differences in framework conditions for research that are still evident between the European regions. Rather, border-crossing clinical research in Europe could be seriously threatened by the ever-increasing legal and bureaucratic requirements while research budgets are being reduced.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   179.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Pfister DG, Johnson DH, Azzoli CG, et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 2004;22:330.

    Article  PubMed  Google Scholar 

  2. Farray D, Mirkovic N, Albain KS. Multimodality therapy for stage III non-small-cell lung cancer. J Clin Oncol 2005;23:3257.

    Article  PubMed  CAS  Google Scholar 

  3. Felip E, Stahel RA, Pavlidis N. ESMO Minimum clinical recommendations for diagnosis, treatment and follow-up of non-small-cell lung cancer (NSCLC). Ann Oncol 2005;16(suppl 1):i28.

    Article  PubMed  Google Scholar 

  4. Gridelli C, Ardizzoni A, Le Chevalier T, et al. Treatment of advanced non-small-cell lung cancer patients with ECOG performance status 2: results of a European experts panel. Ann Oncol 2004;15:419.

    Article  PubMed  CAS  Google Scholar 

  5. Gridelli C, Aapro M, Ardizzoni A, et al. Treatment of advanced non-small-cell lung cancer in the elderly: results of an international expert panel. J Clin Oncol 2005;23:3125.

    Article  PubMed  CAS  Google Scholar 

  6. Pincus M, Reddy S, Lee MS, et al. Preoperative combined modality therapy for stage III MO non-small cell lung carcinoma. Int J Radiat Oncol Biol Phys 1988;15:189.

    PubMed  CAS  Google Scholar 

  7. Albain KS, Crowley JJ, Turrisi AT 3rd, et al. Concurrent cisplatin, etoposide, and chest radiotherapy in pathologic stage IIIB non-small-cell lung cancer: a Southwest Oncology Group phase II study, SWOG 9019. J Clin Oncol 2002;20:3454.

    Article  PubMed  CAS  Google Scholar 

  8. Eberhardt W, Wilke H, Stamatis G, et al. Preoperative chemotherapy followed by concurrent chemoradiation therapy based on hyperfractionated accelerated radiotherapy and definitive surgery in locally advanced non-small-cell lung cancer: mature results of a phase II trial. J Clin Oncol 1998;16:622.

    PubMed  CAS  Google Scholar 

  9. Rosell R, Gomez-Codina J, Camps C, et al. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N Engl J Med 1994;330:153

    Article  PubMed  CAS  Google Scholar 

  10. Rosell R, Gomez-Codina J, Camps C, et al. Preresectional chemotherapy in stage IIIA non-small-cell lung cancer: a 7-year assessment of a randomized controlled trial. Lung Cancer 1999;26:7.

    Article  PubMed  CAS  Google Scholar 

  11. Depierre A, Milleron B, Moro-Sibilot D, et al. Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and IIIa non-small-cell lung cancer. J Clin Oncol 2002;20:247.

    Article  PubMed  Google Scholar 

  12. Splinter TA, van Schil PE, Kramer GW, et al. Randomized trial of surgery versus radiotherapy in patients with stage IIIA (N2) non small-cell lung cancer after a response to induction chemotherapy. EORTC 08941. Clin Lung Cancer 2000;2:69:73.

    Article  PubMed  CAS  Google Scholar 

  13. De Marinis F, Nelli F, Migliorino MR, et al. Gemcitabine, paclitaxel, and cisplatin as induction chemotherapy for patients with biopsy-proven stage IIIA(N2) non-small cell lung carcinoma: a phase II multicenter study. Cancer 2003;98:1707.

    Article  PubMed  CAS  Google Scholar 

  14. Manegold, C, Biesma B, Smit H, et al. Docetaxel and cisplatin as induction chemotherapy in stage IIIA N2 non-small cell lung cancer (NSCLC): an EORTC phase II trial (08984). J Clin Oncol (meeting abstracts) 2004;22(14 suppl):7166.

    Google Scholar 

  15. Van Zandwijk N, Smit EF, Kramer GW, et al. Gemcitabine and cisplatin as induction regimen for patients with biopsy-proven stage IIIA N2 non-small-cell lung cancer: a phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group (EORTC 08955). J Clin Oncol 2000;18:2658.

    PubMed  Google Scholar 

  16. Betticher DC, Hsu Schmitz SF, Totsch M, et al. Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small-cell lung cancer: a multi-center phase II trial. J Clin Oncol 2003;21:1752.

    Article  PubMed  CAS  Google Scholar 

  17. Betticher DC, Rosell R. Neoadjuvant treatment of early-stage resectable non-small-cell lung cancer. Lung Cancer 2004;46(suppl 2):S23.

    Article  PubMed  Google Scholar 

  18. O’Brien ME, Smith I, Postmus PE, et al. Taxol and carboplatin induction chemotherapy in stage III non-small cell lung cancer (NSCLC): an EORTC 08958 phase II trial. J Clin Oncol (meeting abstracts) 1999;18:492a.

    Google Scholar 

  19. Thomas M, Rube C, Semik M, et al. Impact of preoperative bimodality induction including twice-daily radiation on tumor regression and survival in stage III non-small-cell lung cancer. J Clin Oncol 1999;17:1185.

    PubMed  CAS  Google Scholar 

  20. Thomas M, Macha HN, Ukena D, et al. Cisplatin/etoposide (PE) followed by twice-daily chemoradiation (hfRT/CT) versus PE alone before surgery in stage III non-small cell lung cancer (NSCLC): a randomized phase III trial of the German Lung Cancer Cooperative Group (GLCCG). J Clin Oncol (meeting abstracts) 2004;22(14 suppl):7004.

    Google Scholar 

  21. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 1995;311:899.

    Google Scholar 

  22. Scagliotti GV, Fossati R, Torri V, et al. Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell lung cancer. J Natl Cancer Inst 2003;95:1453.

    PubMed  CAS  Google Scholar 

  23. Waller D, Peake MD, Stephens RJ, et al. Chemotherapy for patients with non-small cell lung cancer: the surgical setting of the Big Lung Trial. Eur J Cardiothorac Surg 2004;26:173.

    Article  PubMed  CAS  Google Scholar 

  24. Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP, Vansteenkiste J. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004;350:351.

    Article  PubMed  Google Scholar 

  25. Kato H, Ichinose Y, Ohta M, et al. A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med 2004;350:1713.

    Article  PubMed  CAS  Google Scholar 

  26. Winton TL, Livingston R, Johnson D, et al. A prospective randomised trial of adjuvant vinorelbine (VIN) and cisplatin (CIS) in completely resected stage 1B and II non small cell lung cancer (NSCLC) Intergroup JBR. 10. J Clin Oncol (meeting abstracts) 2004;22(14 suppl):7018.

    Google Scholar 

  27. Winton T, Livingston R, Johnson D, et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 2005;352:2589.

    Article  PubMed  CAS  Google Scholar 

  28. Strauss GM, Herndon J, Maddaus MA, et al. Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in stage IB non-small cell lung cancer (NSCLC): report of Cancer and Leukemia Group B (CALGB) Protocol 9633. J Clin Oncol (meeting abstracts) 2004;22(14 suppl):7019.

    Google Scholar 

  29. Douillard JY, Rosell R, Delena M, Legroumellec A, Torres A, Carpagnano F. ANITA: phase III adjuvant vinorelbine (N) and cisplatin (P) versus observation (OBS) in completely resected (stage I-III) non-small-cell lung cancer (NSCLC) patients (pts): final results after 70-month median follow-up. On behalf of the Adjuvant Navelbine International Trialist Association. J Clin Oncol (meeting abstracts) 2005;23(16 suppl):7013.

    Google Scholar 

  30. Dillman RO, Herndon J, Seagren SL, Eaton WL Jr, Green MR. Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial. J Natl Cancer Inst 1996;88:1210.

    PubMed  CAS  Google Scholar 

  31. Schaake-Koning C, van den Bogaert W, Dalesio O, et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med 1992;326:524.

    Article  PubMed  CAS  Google Scholar 

  32. Sause W, Kolesar P, Taylor SI, et al. Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. Chest 2000;117:358.

    Article  PubMed  CAS  Google Scholar 

  33. Le Chevalier T, Arriagada R, Quoix E, et al. Radiotherapy alone versus combined chemotherapy and radiotherapy in unresectable non-small cell lung carcinoma. Lung Cancer 1994;10(suppl 1):S239.

    Article  PubMed  Google Scholar 

  34. Curran WJ, Scott CB, Langer CJ, et al. Long-term benefit is observed in a phase III comparison of sequential vs concurrent chemo-radiation for patients with unresected stage III NSCLC: RTOG 9410 [abstract 2499]. Proc Am Soc Clin Oncol 2003;22:621.

    Google Scholar 

  35. Furuse K, Fukuoka M, Kawahara M, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 1999;17:2692.

    PubMed  CAS  Google Scholar 

  36. Pierre F, Maurice P, Gilles R, et al. A randomized phase III trial of sequential chemo-radiotherapy versus concurrent chemo-radiotherapy in locally advanced non small cell lung cancer (NSCLC) (GLOT-GFPC NPC 95-01 study) [abstract]. 2001 ASCO Annual Meeting 2001;20:1246.

    Google Scholar 

  37. Gandara DR, Chansky K, Albain KS, et al. Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer: phase II Southwest Oncology Group Study S9504. J Clin Oncol 2003;21:2004.

    Article  PubMed  CAS  Google Scholar 

  38. Zatloukal P, Petruzelka L, Zemanova M, et al. Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized study. Lung Cancer 2004;46:87.

    Article  PubMed  Google Scholar 

  39. Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000;18:2095.

    PubMed  CAS  Google Scholar 

  40. Fossella FV, DeVore R, Kerr RN, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-small Cell Lung Cancer Study Group. J Clin Oncol 2000;18:2354.

    PubMed  CAS  Google Scholar 

  41. Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004;22:1589.

    Article  PubMed  CAS  Google Scholar 

  42. Heymach JV, Dong RP, Dimery I, et al. ZD6474, a novel antiangiogenic agent, in combination with docetaxel in patients with NSCLC: results of the run-in phase of a two-part, randomized phase II study. J Clin Oncol (meeting abstracts) 2004;22(14 suppl):3051.

    Google Scholar 

  43. Kosmidis P, Mylonakis N, Nicolaides C, et al. Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small-cell lung cancer: a phase III ran domized trial. J Clin Oncol 2002;20:3578.

    Article  PubMed  CAS  Google Scholar 

  44. Georgoulias V, Ardavanis A, Tsiafaki X, et al. Vinorelbine plus cisplatin versus docetaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III ran domized trial. J Clin Oncol 2005;23:293.

    Article  CAS  Google Scholar 

  45. Gridelli C, Perrone F, Gallo C, et al. Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst 2003;95:362.

    Article  PubMed  CAS  Google Scholar 

  46. Rosell R, Cobo M, Isla D, et al. ERCC1 mRNA-based randomized phase III trial of docetaxel (doc) doublets with cisplatin (cis) or gemcitabine (gem) in stage IV non-small-cell lung cancer (NSCLC) patients (p). J Clin Oncol (meeting abstracts) 2005;23(16 suppl):7002.

    Google Scholar 

  47. Rudd RM, Gower NH, Spiro SG, et al. Gemcitabine plus carboplatin versus mitomycin, ifosfamide, and cisplatin in patients with stage IIIB or IV non-small-cell lung cancer: a phase III randomized study of the London Lung Cancer Group. J Clin Oncol 2005;23:142.

    Article  PubMed  CAS  Google Scholar 

  48. Giaccone G, Herbst RS, Manegold C, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial —INTACT 1. Clin Oncol 2004;22:777.

    Article  CAS  Google Scholar 

  49. Herbst RS, Giaccone G, Schiller JH, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial —INTACT 2. Clin Oncol 2004;22:785.

    Article  CAS  Google Scholar 

  50. Herbst RS, Prager D, Hermann R, et al. TRIBUTE: a phase III trial of erlotinib HC1 (OSI-774) combined with carboplatin and paclitaxel (CP) chemotherapy in advanced non-small cell lung cancer (NSCLC). J Clin Oncol (meeting abstracts) 2004;22(14 suppl):7011.

    Google Scholar 

  51. Gatzemeier U, Pluzanska A, Szczesna A, et al. Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC). J Clin Oncol (meeting abstracts) 2004;22(14 suppl):7010.

    Google Scholar 

  52. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol 2003;21:2237.

    Article  PubMed  CAS  Google Scholar 

  53. Sandier AB, Gray R, Brahme J, et al. Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC # 704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): an Eastern Cooperative Oncology Group (ECOG) trial-E4599. Clin Oncol (meeting abstracts) 2005;22(LBA4):1090s.

    Google Scholar 

  54. Leichman G, Gravenor D, Woytowitz D, et al. CPG 7909, a TLR9 agonist, added to first line taxane/platinum for advanced non-small cell lung cancer: a randomized, controlled phase II study. J Clin Oncol (meeting abstracts) 2005;23(16 suppl):7039.

    Google Scholar 

  55. Mueller A, Thatcher N, Kortsik C, et al. A phase II/III randomized study in advanced non-small cell lung cancer (NSCLC) with first line combination versus sequential gemcitabine and docetaxel: interim study results. J Clin Oncol (meeting abstracts) 2004;22(14 suppl):7095.

    Google Scholar 

  56. Manegold C, Thatcher N, Kortsik C, et al. A phase II/III randomized study in advanced non-small cell lung cancer (NSCLC) with first line combination versus sequential gemcitabine (G) and docetaxel (D): update on quality of life (QoL), toxicity, and costs. J Clin Oncol (meeting abstracts) 2005;23(16 suppl):7057.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, Heidelberg University Medical Center, Mannheim, Germany

    Christian Manegold, Annette Mueller & Sebastian Belle

Authors
  1. Christian Manegold
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Annette Mueller
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sebastian Belle
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Sotiria General Hospital, Athens Medical School, Athens, Greece

    Konstantinos N. Syrigos MD, PhD

  2. Royal Marsden NHS Trust Hospitals, London, UK

    Christopher M. Nutting MB BA, MD, FRCR

  3. Evangelismos General Hospital, Athens Medical School, Athens, Greece

    Charis Roussos MD, MSc, PhD, MRS, FRCP(C)

  4. Faculty of Medicine, McGill University, Montreal, Canada

    Charis Roussos MD, MSc, PhD, MRS, FRCP(C)

Rights and permissions

Reprints and permissions

Copyright information

© 2006 Springer Berlin Heidelberg

About this chapter

Cite this chapter

Manegold, C., Mueller, A., Belle, S. (2006). Non-Small-Cell Lung Cancer: Clinical Studies in Europe. In: Syrigos, K.N., Nutting, C.M., Roussos, C. (eds) Tumors of the Chest. Springer, Berlin, Heidelberg . https://doi.org/10.1007/3-540-31040-1_37

Download citation

  • DOI: https://doi.org/10.1007/3-540-31040-1_37

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-31039-6

  • Online ISBN: 978-3-540-31040-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation